Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 247)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.721
Gesamt: 345.721
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,4420
EUR
+0,70 %
+0,0100 EUR
Letzter Kurs 22.04.24 Tradegate
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
3,5800 | +922,86 | |
0,8800 | +95,56 | |
29,10 | +21,25 | |
0,9650 | +14,88 | |
7,9900 | +14,14 |
Wertpapier | Kurs | Perf. % |
---|---|---|
14,510 | -32,32 | |
1,3700 | -32,84 | |
1,4100 | -32,86 | |
3,6400 | -38,62 | |
0,7000 | -61,85 |
Beitrag zu dieser Diskussion schreiben
jaja, genau, Brat das Chicken, kennen wir schon
Schön wärs...
Galena Biopharma (GALE) To Open At $10.25 Following The Official Confirmation Of Acquisition By Berkshire Hathaway Predicts Sierra World Equity Review
HEADLINE: Galena Biopharma (GALE) To Open At $10.25 Following The Official Confirmation Of Acquisition By Berkshire Hathaway Predicts Sierra World Equity Review.
Sierra and her team were the first to call the potential Berkshire Hathaway buyout of Galena Biopharma.
Berkshire Hathaway Moving To Acquire Galena Biopharma (GALE) Eyeing A Winner In Breast Cancer Pipeline Drug NeuVax..
Now Sierra is projecting that the share price of Galena Biopharma will open at $10.25 after the official news is released. Thanks to all who joined Sierra and her team for Sunday afternoons conference call from Las Vegas, due to popular demand Sierra plans to continue hosting a bi-monthly conference call where her team will reveal their insights, leads and answer any and all questions on any stocks that Sierra has posted about.
http://sierraworldequityreview.blogspot.ch/2014/03/galena-bi…
Galena Biopharma (GALE) To Open At $10.25 Following The Official Confirmation Of Acquisition By Berkshire Hathaway Predicts Sierra World Equity Review
HEADLINE: Galena Biopharma (GALE) To Open At $10.25 Following The Official Confirmation Of Acquisition By Berkshire Hathaway Predicts Sierra World Equity Review.
Sierra and her team were the first to call the potential Berkshire Hathaway buyout of Galena Biopharma.
Berkshire Hathaway Moving To Acquire Galena Biopharma (GALE) Eyeing A Winner In Breast Cancer Pipeline Drug NeuVax..
Now Sierra is projecting that the share price of Galena Biopharma will open at $10.25 after the official news is released. Thanks to all who joined Sierra and her team for Sunday afternoons conference call from Las Vegas, due to popular demand Sierra plans to continue hosting a bi-monthly conference call where her team will reveal their insights, leads and answer any and all questions on any stocks that Sierra has posted about.
http://sierraworldequityreview.blogspot.ch/2014/03/galena-bi…
Levi & Korsinsky, LLP Launches Investigation of GALENA BIOPHARMA, INC. for Possible Breaches of Fiduciary Duty
http://finance.yahoo.com/news/shareholder-alert-levi-korsins…
http://finance.yahoo.com/news/shareholder-alert-levi-korsins…
GALE hebelt sich hoch.
Gute News von heute treiben den Kurs!
Insider kaufen weiter !
Gute News von heute treiben den Kurs!
Insider kaufen weiter !
Ja kam heute 13:21 per E-Mail von rbernarda@galenabiopharma.com
Ab besten dort schreiben wenn Du keine Mails von Galena bekommst. Ev. hast aber auch vergessen deine Eintragung zu bestätigen... Kommt direkt nach einer Anmeldung per Mail.
Ab besten dort schreiben wenn Du keine Mails von Galena bekommst. Ev. hast aber auch vergessen deine Eintragung zu bestätigen... Kommt direkt nach einer Anmeldung per Mail.
Antwort auf Beitrag Nr.: 46.542.317 von Aurum2010 am 28.02.14 15:05:29Jupp besser
Kommt ja von der gale Seite. Kam die Nachricht per Newsletter? Hatte mich doch eigentlich auch im Newsletter eingetragen
Was meinst du. Halten wir heute mal die 4????
Kommt ja von der gale Seite. Kam die Nachricht per Newsletter? Hatte mich doch eigentlich auch im Newsletter eingetragen
Was meinst du. Halten wir heute mal die 4????
Antwort auf Beitrag Nr.: 46.541.559 von Aurum2010 am 28.02.14 13:34:42Link funzt net
Aber Nachricht liest sich trotzdem gut. Scheint wohl der Grund zu sein warum wir im Pre aktuell schon 7% im Plus sind
Na hoffentlich halten wir das auch mal wieder auf schlusskurs Basis.
Aber Nachricht liest sich trotzdem gut. Scheint wohl der Grund zu sein warum wir im Pre aktuell schon 7% im Plus sind
Na hoffentlich halten wir das auch mal wieder auf schlusskurs Basis.
Galena Biopharma Bolsters NeuVax(TM) (nelipepimut-S) Intellectual Property With Patent Acceptance in Australia
PORTLAND, Ore., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that it has received a Notice of Acceptance from the Australian Patent Office for a patent covering the use of Galena's development product candidate, NeuVax™ (nelipepimut-S), a HER2/neu peptide vaccine, for inducing protective or therapeutic immunity to breast cancer recurrence in patients having low-to-intermediate HER2 IHC ratings of 1+ or 2+ and a FISH rating of less than 2.0 ± 20% for CYP17 to HER2/neu gene expression ratio. The patent provides NeuVax the exclusivity for this indication until 2028, not including any patent term extensions.
"With our Phase 3 PRESENT trial currently ongoing in 13 countries, the continued addition of commercial partnerships, and a future clinical trial to be conducted in India, we are positioning NeuVax to be a potential treatment option for HER2 cancer patients worldwide," stated Mark J. Ahn, Ph.D., President and CEO. "This Australian patent strengthens our global intellectual property portfolio to potentially provide a tool to prevent recurrence in women with breast cancer."
NeuVax is currently in two clinical breast cancer trials, including the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial and a Phase 2b trial in combination with Herceptin® (trastuzumab). A Phase 2 gastric cancer trial is also expected to initiate this year and will be run by Galena's partner in India, Dr. Reddy's.
http://investors.galenabiopharma.co/releasedetail.cfm?Releas…" target="_blank" rel="nofollow ugc noopener">
http://investors.galenabiopharma.co/releasedetail.cfm?Releas…
PORTLAND, Ore., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that it has received a Notice of Acceptance from the Australian Patent Office for a patent covering the use of Galena's development product candidate, NeuVax™ (nelipepimut-S), a HER2/neu peptide vaccine, for inducing protective or therapeutic immunity to breast cancer recurrence in patients having low-to-intermediate HER2 IHC ratings of 1+ or 2+ and a FISH rating of less than 2.0 ± 20% for CYP17 to HER2/neu gene expression ratio. The patent provides NeuVax the exclusivity for this indication until 2028, not including any patent term extensions.
"With our Phase 3 PRESENT trial currently ongoing in 13 countries, the continued addition of commercial partnerships, and a future clinical trial to be conducted in India, we are positioning NeuVax to be a potential treatment option for HER2 cancer patients worldwide," stated Mark J. Ahn, Ph.D., President and CEO. "This Australian patent strengthens our global intellectual property portfolio to potentially provide a tool to prevent recurrence in women with breast cancer."
NeuVax is currently in two clinical breast cancer trials, including the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial and a Phase 2b trial in combination with Herceptin® (trastuzumab). A Phase 2 gastric cancer trial is also expected to initiate this year and will be run by Galena's partner in India, Dr. Reddy's.
http://investors.galenabiopharma.co/releasedetail.cfm?Releas…" target="_blank" rel="nofollow ugc noopener">
http://investors.galenabiopharma.co/releasedetail.cfm?Releas…
Zitat von lunatics: heute wird,s grün
Leider nicht - der kurzfristige Abwärtstrend ist hartnäckiger als gedacht.
@galena Management: wir brauchen mal einen kleinen schups!
Hallo Lunatics,
habe mir heute noch mal in ruhe deinen einstellten Artikel von Roche angesehen.
Wie siehst du die Chance, dass galena das modifizierte Medikament selbst zur produktreife bringt
und vermarkten kann und
Welches Jahr hältst du für realistisch? (2016?)
VG